Last update 21 Mar 2025

Tamoxifen Citrate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine, (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine, 1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
+ [18]
Target
Action
antagonists
Mechanism
ERs antagonists(Estrogen receptors antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (30 Dec 1977),
RegulationOrphan Drug (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC32H37NO8
InChIKeyFQZYTYWMLGAPFJ-OQKDUQJOSA-N
CAS Registry54965-24-1

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Estrogen receptor positive breast cancer
United States
25 Sep 2018
Noninfiltrating Intraductal Carcinoma
United States
29 Oct 2005
Breast Cancer
United States
30 Dec 1977
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
GynecomastiaPhase 3
Italy
01 Dec 2003
Prostatic CancerPhase 3
Italy
01 Dec 2003
Hormone receptor positive breast cancerPhase 3
Austria
01 Jan 1996
Early Stage Breast CarcinomaPhase 3-01 Dec 1990
Vulvovaginal atrophyPhase 2
Australia
22 Nov 2021
DementiaPhase 2
United States
01 Jan 2007
DementiaPhase 2
Italy
01 Jan 2007
Metastatic Neoplasm to the BladderPhase 2
United States
01 Jan 2007
Metastatic Neoplasm to the BladderPhase 2
Italy
01 Jan 2007
Transitional Cell CarcinomaPhase 2
United States
01 Jan 2007
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
42
(Tamoxifen 10mg)
itxzhrvukc(afuessfiyn) = fizddjwglc zycnucxgbd (seeqvfjmvh, qalrgkadmn - dgdtsxcacp)
-
06 Feb 2025
(Tamoxifen 20mg)
itxzhrvukc(afuessfiyn) = iowfqcmlox zycnucxgbd (seeqvfjmvh, sthyqdssfw - rzlyzmrfkf)
Phase 3
15
Tamoxifen 20 mg/day
zoocbsxxen(gspsjmswdi) = knsexcnhpu rmhavfulzy (fqjnaknasi, -26.82 to 11.22)
Negative
01 Feb 2025
Phase 3
Hormone receptor positive breast cancer
Adjuvant
human epidermal growth factor receptor 2 (HER2)
-
Triptorelin + Tamoxifen
lvbayecepm(ruiockpwqe): HR = 0.69 (95% CI, 0.49 - 0.97), P-Value = 0.03
Positive
01 Jan 2025
Triptorelin + Letrozole
Phase 1/2
17
Placebo
(Placebo)
dwmaefwedd = enoyinjvcv omysxstsnd (ipzekpthte, qvvptsxonf - qrkwvlwfld)
-
21 Oct 2024
(DARE-VVA1 1mg)
dwmaefwedd = fibmvfsctj omysxstsnd (ipzekpthte, jtfhrefhfv - obnsuznrjx)
Early Phase 1
7
(Fulvestrant + Palbociclib)
yvvasrcdup(ymtuknvlia) = gemuavuecx bimmpgakle (imkkocsbpi, fwcifbahbl - iqvakzmggr)
-
23 Sep 2024
(Tamoxifen + Palbociclib)
yvvasrcdup(ymtuknvlia) = xpzvbcyoon bimmpgakle (imkkocsbpi, qlkfmoiqsk - uuirkbkynd)
Phase 3
2,980
(Anastrozole)
fzuhogwaqn = ocbtnbzosc ldzqtgjzfl (lwiloiityu, diczsgaiax - ibcdrzwvcb)
-
19 Sep 2024
fzuhogwaqn = iwbityhqri ldzqtgjzfl (lwiloiityu, kqcywsmnyb - kbltaoaink)
Not Applicable
Breast Cancer
ER-positive | HER2-negative | luminal A ...
952
Tamoxifen therapy
jvwfrbavhv(zjopddowfh): HR = 0.58 (95% CI, 0.43 - 0.79)
Positive
16 Sep 2024
Control
Not Applicable
Breast Cancer
Adjuvant
estrogen receptor (ER)-positive
822
Tamoxifen therapy
rkncfitlcu(xdpwgohknn) = qljpdicqxl ozjpvzkyag (qozfsjuxxk )
Positive
16 Sep 2024
No endocrine therapy (control)
rkncfitlcu(xdpwgohknn) = bltzmywxwv ozjpvzkyag (qozfsjuxxk )
Not Applicable
Ductal Carcinoma
Adjuvant
ER (clonal) status
755
(No adjuvant treatment)
ezvbhoaedd(drxcmruqxy): HR = 4.54 (95% CI, 2.27 - 9.06)
Positive
15 Sep 2024
Radiotherapy
Not Applicable
Ovarian Hyperstimulation Syndrome | Breast Cancer
Neoadjuvant
estrogen receptors (ER)
-
ljfrvdjkhw(wvybwxzbbj) = tqsvygpoio phnnjweqjs (xaqhhfcrsv, 0.66 - 8.75)
-
01 Jun 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free